Fosun Pharma has formed technological platforms for innovative small molecule drugs, antibody drugs, and cell therapy with a focus on key disease areas including oncology and immunomodulation, metabolism and digestive system, and central nervous system. Fosun Pharma also vigorously explores cutting-edge technologies, such as RNA, gene therapy, ADC and PROTAC, to enhance its innovation capabilities.

Guided by the 4IN strategy (Innovation, Internationalization, Intelligentization, and Integration), Fosun Pharma will uphold the development model of “innovation transformation, integrated operation, and steady growth", with the mission of creating shareholder values through strengthening its independent R&D and external cooperation and enriching its product pipelines, as well as promoting the global networks and enhancing operational efficiency. Fosun Pharma will actively promote the digital and physical business layout in the pharmaceutical and healthcare industry and is committed to becoming a first-class enterprise in the global medical and health market.

39,005Million FY2021 Revenue
3,277Million FY 2021 Net Profit Attributable to Shareholders of the Listed Company After the One-off Gain
4,975Million FY 2021 R&D Expenditure
36,279 Global Employees
Five-Star(Excellence) 2021 Corporate Social Responsibility Report Rating
A MSCI ESG Rating
As of December 31, 2021
Unit: RMB million

Shanghai Fosun Pharmaceutical (Group) Co. Ltd. Videos

mRNA COVID-19 Vaccines - Video